Is Enanta Pharmaceuticals, Inc. (ENTA) a Buy, Sell, or Hold?
NASDAQ : ENTA
Enanta Pharmaceuticals, Inc.
$13.23 USD
$0.12 (0.92%)
- Volume
- 97.46K
- Average Volume
- 212.6K
- Market Capitalization
- $307.16M
- P/E Ratio
- -4.83
- Dividend Yield
- 0.00%
- Price Target
- $20.00
- Year High
- $17.15
- Year Low
- $6.44
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.84
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Jay R. Luly |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ENTA |
| CUSIP | 29251M106 |
| CIK | 0001177648 |
| Web | https://www.enanta.com |
| Phone | 617 607 0800 |
| Currency | USD |
| Employees | 120 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 1.60 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.84 |
| Quick Ratio | 3.84 |
| Cash Ratio | 0.75 |
Sales & Book Value
| Annual Sales | $65.32M |
| Price / Sales | 4.44 |
| Cash Flow | -0.45 |
| Price / Cash Flow | -31.97 |
| Price / Book | 2.43 |
Price Target and Rating
| Average Stock Price Forecast | $20.00 |
| High Stock Price Forecast | $20.00 |
| Low Stock Price Forecast | $20.00 |
| Forecast Upside/Downside | -33.85% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 19 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$3.84 |
| Trailing P/E Ratio | -4.83 |
| PEG Ratio | -0.09 |
| P/E Growth | -0.09 |
| Net Income | -$81.89M |
| Net Margin | -89.56% |
| Pretax Margin | -89.42% |
| Return on Equity | -64.04% |
| Return on Assets | -19.70% |
Financials Score
| AltmanZ Score | -0.81 |
| Piotroski Score | 3.00 |
| Working Capital | 131.97M |
| Total Assets | 314.7M |
| Ebit | -51.49M |
| Market Cap | 304.37M |
| Total Liabilities | 198.12M |
Poll Results
About Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmac ... euticals, Inc. operates from its principal office located in Watertown, Massachusetts.
Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last?
2026-06-24 10:16:11
Enanta Pharmaceuticals (ENTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
2026-06-23 05:10:00
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that the European Commission has approved MAVIRET® (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral (DAA) therapy, for the treatment of acute HCV infection without cirrhosis or with compensated cirrhosis in adults and children aged 3 years and older.
2026-06-18 07:00:00
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced it is advancing zelicapavir into a registrational Phase 2b/3 clinical trial in adults at high risk of severe outcomes from RSV infection after a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA). The Phase 2b portion of the trial will confi.
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
2026-05-28 08:00:00
[url="]Enanta Pharmaceuticals, Inc.[/url] (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
2026-05-28 07:00:00
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, and Tara L. Kieffer, Ph.D., Chief Product Strategy Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 4, 2026 at 11:40 a.m. ET in New York, NY. A live w.
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates
2026-05-11 18:10:18
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to a loss of $1.06 per share a year ago.
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
2026-05-11 16:01:00
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal second quarter ended March 31, 2026. “Since the inception of our immunology portfolio targeting type 2 diseases, our team has worked diligently to advance highly selective inhibitors of KIT, STAT6 and MRGPRX2 designed to enable convenient or.
Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last?
2026-05-07 10:06:10
Enanta Pharmaceuticals (ENTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Frequently Asked Questions
-
What is the current Enanta Pharmaceuticals, Inc. (ENTA) stock price?
-
Enanta Pharmaceuticals, Inc.(NASDAQ:ENTA) stock price is $13.23 in the last trading session. During the trading session, ENTA stock reached the peak price of $17.15 while $6.435 was the lowest point it dropped to. The percentage change in ENTA stock occurred in the recent session was 0.92% while the dollar amount for the price change in ENTA stock was $0.12.
-
ENTA's industry and sector of operation?
-
The NASDAQ listed ENTA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ENTA?
-
Nathaniel S. Gardiner | Consultant
Tara Lynn Kieffer | Chief Product Strategy Officer
Brendan Luu | Chief Business Officer
Scott T. Rottinghaus | Chief Medical Officer
Harry R. Trout | VP of Finance & Interim Principal Financial Officer -
How many employees does ENTA have?
-
Number of ENTA employees currently stands at 120. ENTA operates from 500 Arsenal Street, Watertown, MA 02472, US.
-
Link for ENTA official website?
-
Official Website of ENTA is: https://www.enanta.com
-
How do I contact ENTA?
-
ENTA could be contacted at phone #617 607 0800 and can also be accessed through its website. ENTA operates from 500 Arsenal Street, Watertown, MA 02472, US.
-
How many shares of ENTA are traded daily?
-
The average number of ENTA shares traded daily for last 3 months was 212.6K.
-
What is the market cap of ENTA currently?
-
The market value of ENTA currently stands at $307.16M with its latest stock price at $13.23